Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVETIRACETAM IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Adjunctive therapy in the treatment of partial-onset seizures in adults and children ≥1 month,Adjunctive therapy in myoclonic seizures in adults and children ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy in primary generalized tonic-clonic seizures in adults and children ≥6 years with idiopathic generalized epilepsy
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD)
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
<10% (negligible); not bound to albumin or alpha-1-acid glycoprotein
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
IV: 100%; Oral: 100% (rapid and complete absorption)
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Cr Cl >80 m L/min: 500-1500 mg every 12h; Cr Cl 50-80: 500-1000 mg every 12h; Cr Cl 30-50: 250-750 mg every 12h; Cr Cl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA black box warnings.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation,Somnolence and fatigue,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (e.g., decreased white blood cell counts),Hypersensitivity reactions including angioedema,Renal impairment requires dose adjustment
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to levetiracetam or any component of the formulation
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Levetiracetam can be taken with or without food. Avoid excessive alcohol consumption as it may increase CNS depression.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure is estimated to be 1-2% of the maternal weight-adjusted dose. No adverse effects have been reported in breastfed infants, but caution is recommended.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy may decrease levetiracetam plasma concentrations by up to 40-60% due to increased clearance. Dose adjustment is often required: monitor serum trough levels and increase dose as needed to maintain therapeutic levels. Postpartum, monitor for potential dose reduction.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor for behavioral and psychiatric symptoms, especially in pediatric patients. Infusion rate should not exceed 5 mg/kg/min. Risk of suicidal thoughts and behavior. Caution in renal impairment; adjust dose based on creatinine clearance. Levetiracetam is not significantly protein-bound and has minimal drug interactions. May cause somnolence, dizziness, and coordination difficulties.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any new or worsening depression, agitation, hostility, or suicidal thoughts immediately.,Do not drive or operate heavy machinery until you know how levetiracetam affects you; it may cause dizziness or sleepiness.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double dose.,Do not stop taking levetiracetam abruptly; this can increase seizure frequency.,Inform all healthcare providers that you take levetiracetam, especially before surgery or emergency treatment.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Levetiracetam, an antiepileptic drug, may potentiate the sedative effects of pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome. This additive pharmacodynamic interaction results in increased central nervous system depression, leading to enhanced drowsiness, dizziness, and impaired psychomotor function. Clinically, patients may experience excessive sedation, reduced alertness, and an increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Thiothixene, a typical antipsychotic, can lower the seizure threshold, increasing the risk of convulsions, particularly in patients with epilepsy. Levetiracetam, an anticonvulsant, may be less effective if seizure threshold is reduced, potentially leading to breakthrough seizures. Additionally, both drugs can cause CNS depression, leading to additive sedation, dizziness, and impaired cognitive function."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVETIRACETAM IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
LEVETIRACETAM IN SODIUM CHLORIDE is a Electrolyte that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVETIRACETAM IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVETIRACETAM IN SODIUM CHLORIDE is: 500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVETIRACETAM IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVETIRACETAM IN SODIUM CHLORIDE is classified as Category A/B. Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.